Heterologous Ad.26.COV2.S versus homologous BNT162b2/mRNA-1273 as a third dose in solid organ transplant recipients seronegative after two-dose mRNA vaccination.

Am J Transplant · 2022 · PMC9111240 · PMID 35429211

Europe PMC DOI

hedged sentence

0.0640

closest p · 1.3× alpha

0.0640

boldest claim

The sentences

did not reach statistical significancep = .064so close (0.05 < p ≤ 0.1)

Post-vaccination kinetics comparing heterologous and homologous vaccine platforms At 1-month post-D3, 63% (22/35) of D3-JJ recipients and 52% (141/269) of D3-mRNA recipients became seropositive ( p = .28, Table 2 ); this difference did not reach statistical significance in weighted analysis (weighted incidence-rate-ratio [wIRR] = 0.98 1.29 1.69 , p = .064, Table 3 ).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.